What Ozempic does to the brain

The drug class called GLP-1 receptor agonists was developed to treat type 2 diabetes. Semaglutide, the active ingredient in Ozempic and Wegovy, lowers blood sugar by mimicking a gut hormone. Then it turned out to also produce significant weight loss. Then it turned out that GLP-1 receptors are not just in the gut and pancreas. They are densely expressed in the brain.

We are now in the middle of figuring out what that means.

The brain receptors

GLP-1 receptors sit on neurons in regions involved in:

• Appetite regulation (hypothalamus, brainstem)
• Reward processing (ventral tegmental area, nucleus accumbens)
• Memory and emotion (hippocampus, amygdala)
• Decision-making (prefrontal cortex)

When a GLP-1 drug crosses the blood-brain barrier, it acts on all of these regions, not just the gut. This explains effects that were originally puzzling.

What seems to be happening

Several effects are now reasonably well documented:

Reduced food craving. The most expected effect, but the mechanism is interesting. GLP-1 drugs do not just suppress hunger. They reduce the rewarding feeling of food. People report that food tastes the same, but they no longer feel pulled toward it.

Reduced addictive behaviour more generally. Early evidence suggests GLP-1 drugs may also reduce alcohol consumption, smoking, and opioid craving. Trials are underway for alcohol use disorder specifically. The common mechanism is likely modulation of the brain's reward system.

Mood and motivation effects. These cut both ways. Some patients report improved mood. Others report flatness, reduced interest, or anhedonia. The literature is currently messy on this.

Possible neuroprotective effects. There is real interest in whether GLP-1 drugs could slow the progression of Alzheimer's disease and Parkinson's disease. A 2024 Phase 3 trial of liraglutide in Alzheimer's showed modest cognitive benefit. Larger trials are running.

What we do not yet know

The story is far from complete. Open questions include:

• Long-term cognitive effects. We have a few years of data. The drugs may be used for decades. The cognitive trajectory of long-term users is unknown.
• Effects on appetite-related reward beyond food. If a drug blunts the brain's response to food reward, does it also blunt other rewards? The reports of emotional flatness suggest this is possible.
• Mechanisms of neuroprotection, if it is real. Anti-inflammatory effects, improved insulin signalling in the brain, and direct receptor effects are all candidates.
• Who responds and who does not. Genetic variation in GLP-1 receptors likely matters but is poorly understood.

What it means for brain health

GLP-1 drugs are reframing a basic question: how much of brain health is metabolic health? The two have always been linked. Insulin resistance is a risk factor for Alzheimer's. Cardiovascular health predicts brain ageing. What is new is a drug class that targets both ends of this connection simultaneously.

If the early signals hold up, the brain effects of GLP-1 drugs may turn out to be at least as important as their effects on the waistline. We are in a moment that biology often produces: a drug developed for one thing turns out to do something much bigger.